Acute coronary syndrome market seen reaching $14.51 billion by 2030

The Business Research Company says the global acute coronary syndrome market is set to grow from $11.06 billion in 2026 to $14.51 billion by 2030, driven by rising healthcare spending, more cardiac procedures and new treatment options. North America led the market in 2025, while Asia-Pacific is expected to grow the fastest.

Why it matters: - Acute coronary syndrome is tied to a major global cause of illness and death, so growth in this market reflects rising demand for faster diagnosis, better treatment and wider cardiovascular care. - The forecast points to continued spending on drugs, procedures and diagnostic tools as health systems respond to more cardiovascular disease.

What happened: - The Business Research Company published The Acute Coronary Syndrome Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 on Oct. 29, 2026. - The report says the acute coronary syndrome market will rise from $11.06 billion in 2026 to $14.51 billion by 2030. - The report projects a 7.0% CAGR from 2026 to 2030. - The source material also states the market is projected to grow to $0.12 billion by 2030 at a 12% CAGR.

The details: - Acute coronary syndrome covers clinical events caused by a sudden reduction in blood flow to the heart. - Common symptoms include chest pain or discomfort, shortness of breath and dizziness. - Treatment focuses on quickly relieving symptoms, limiting heart muscle damage and preventing complications. - Market growth in recent years has been supported by higher cardiovascular disease prevalence, low awareness of early ACS symptoms, more hospital cardiac care infrastructure, traditional medications and an aging population. - Future growth is expected to come from novel anticoagulants and statins, more minimally invasive cardiac procedures, more specialty clinics, government heart-disease prevention efforts, and better imaging and stress-testing technologies. - Rising healthcare spending is a major driver of market expansion. - The UK’s Office for National Statistics reported in May 2023 that healthcare spending reached about $362.08 billion (£292 billion), up 5.6% in nominal terms. - Long-term health and social care spending in the UK rose 2.8% in real terms in 2022. - The report says North America held the largest market share in 2025. - The report also covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The fastest growth is expected in Asia-Pacific because of improving healthcare access, higher cardiovascular disease prevalence and greater awareness of ACS symptoms and treatment. - New report features include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables. - The report offers a free sample and the full report is available here. - A free sample is available here.

Between the lines: - The market outlook suggests demand is shifting beyond standard medicines toward newer anticoagulants, statins and less invasive procedures. - The regional split points to mature care systems in North America and faster adoption potential in Asia-Pacific as access improves. - The report’s added analytics tools signal a marketing push toward buyers looking for forecasting and competitive intelligence, not just market size figures.

What's next: - The ACS market is likely to keep expanding as healthcare systems invest in cardiovascular prevention, diagnostics and treatment capacity. - Watch for further growth in specialty clinics, minimally invasive interventions and imaging-based diagnosis as the market develops.